Debut Plus

₹2,506.3

▲ +22.6 +0.91%

17 Jul 2026

NSE Listed

GlaxoSmithKline Pharma Ltd. (GLAXO)

Volume: 49,110Avg Vol 1W: 62,872.6Avg Vol 1M: 90,382.252W Range:₹2,088.1₹3,227.2
NSE BSE www.gsk-india.com
Key Ratios
Checked 20h ago
Market Cap₹41,731 Cr
Current Price₹2,506.3
Previous Close₹2,483.7
High / Low (52w)₹3,227.2 / ₹2,088.1
Volume49,110
Avg Vol (1W)62,872.6
Avg Vol (1M)90,382.2
Stock P/E38.23
Book Value₹132.3
Dividend Yield—
ROE48.3%
ROA—
Revenue (TTM)₹3,967 Cr
Revenue Growth—
Profit Margin—
Total Debt₹0 Cr
Shares Outstanding—
Face Value₹10
EPS (TTM)₹59.73
P/B17.26
Debt / Equity0.01
50 DMA₹2,322.43
200 DMA₹2,455.05
Day change+0.91%
Price Chart
₹2,506.3▼ 20.88% · 1Y
₹3197₹21035.2L
2025-07-16
2026-07-15

20-day avg volume: 90K shares

Pros
  • Healthy return on equity of 48.3%.
  • Company is almost debt-free.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹815 Cr₹1,011 Cr₹949 Cr₹974 Cr₹805 Cr₹980 Cr₹1,041 Cr₹995 Cr
EBITDA₹250 Cr₹339 Cr₹308 Cr₹359 Cr₹279 Cr₹352 Cr₹383 Cr₹374 Cr
Net Profit₹182 Cr₹253 Cr₹230 Cr₹263 Cr₹205 Cr₹257 Cr₹296 Cr₹278 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue₹3,230 Cr₹3,303 Cr₹3,036 Cr₹3,354 Cr₹3,352 Cr₹3,576 Cr₹3,895 Cr₹3,967 Cr
EBITDA₹655 Cr₹654 Cr₹630 Cr₹769 Cr₹839 Cr₹962 Cr₹1,257 Cr₹1,388 Cr
Net Profit₹445 Cr₹93 Cr₹358 Cr₹1,695 Cr₹611 Cr₹590 Cr₹928 Cr₹1,036 Cr
EPS26.295.521.14100.0436.0534.8354.7661.15
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹3,911 Cr₹3,136 Cr₹3,115 Cr₹4,633 Cr₹3,327 Cr₹3,557 Cr₹4,108 Cr₹4,324 Cr
Total Liabilities₹1,771 Cr₹1,315 Cr₹1,636 Cr₹1,970 Cr₹1,585 Cr₹1,779 Cr₹2,157 Cr₹2,056 Cr
Equity₹2,140 Cr₹1,821 Cr₹1,478 Cr₹2,663 Cr₹1,741 Cr₹1,778 Cr₹1,951 Cr₹2,267 Cr
Total Debt————————
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹618 Cr₹704 Cr₹743 Cr₹959 Cr₹756 Cr₹976 Cr₹1,372 Cr₹1,222 Cr
Investing₹-143 Cr₹-57 Cr₹418 Cr₹-406 Cr₹808 Cr₹9 Cr₹-46 Cr₹397 Cr
Financing₹-358 Cr₹-428 Cr₹-696 Cr₹-524 Cr₹-1,543 Cr₹-561 Cr₹-769 Cr₹-737 Cr
Free Cash Flow₹618 Cr₹704 Cr₹743 Cr₹959 Cr₹756 Cr₹976 Cr₹1,372 Cr₹1,222 Cr
Shareholding
Promoter 75% Institutions 12.59% Public 12.41%
Efficiency & Working Capital
ROCE61.2%
Interest Coverage516
Dividend Payout—
Debtor Days26 d
Inventory Days44 d
Payable Days54 d
Cash Conversion Cycle15 d
Working Capital Days70 d
Shareholding Details

As of 2026-06-30

Promoter75%
FII4.8%
DII7.8%
Institutions12.6%
Public12.4%
Promoter Pledge0%
No. of Shareholders1,26,087
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters75%75%75%75%75%75%75%75%75%75%75%75%
FIIs2.5%2.9%3.5%4%4.4%4.5%4.5%4.9%4.8%4.6%4.6%4.8%
DIIs10%8.5%7.9%7.5%7.3%7.3%7.8%7.7%7.8%7.7%7.7%7.8%
Public12.5%13.5%13.6%13.5%13.3%13.2%12.7%12.4%12.5%12.7%12.7%12.4%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders1,15,2661,14,6631,18,9941,18,5151,19,2281,19,6251,21,8851,23,6291,22,9041,22,4601,21,7631,26,087
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Glaxo Group LimitedShareholding of Promoter and Promoter Group36%6.10 Cr
Glaxosmithkline Pte LimitedShareholding of Promoter and Promoter Group28.1%4.76 Cr
Eskaylab LimitedShareholding of Promoter and Promoter Group6.9%1.18 Cr
Burroughs Wellcome International LimitedShareholding of Promoter and Promoter Group4%67,20,000
Lici Asm Non ParPublic Shareholding1.1%18,26,540
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Glaxo Group Limited00%2026-06-30
Eskaylab Limited00%2026-06-30
Burroughs Wellcome International Limited00%2026-06-30
Glaxosmithkline Pte Limited00%2026-06-30
Lici Asm Non Par00%2026-06-30
Glaxo Group Limited00%2026-03-31
Eskaylab Limited00%2026-03-31
Burroughs Wellcome International Limited00%2026-03-31
Glaxosmithkline Pte Limited00%2026-03-31
Lici Asm Non Par00%2026-03-31
Glaxo Group Limited00%2025-12-31
Eskaylab Limited00%2025-12-31
Board of Directors
NameDesignationYear
Renu S. KarnadChairman & Non Executive Dir.2026
Bhushan AkshikarManaging Director2026
Subesh WilliamsNon Executive Director2026
Manu AnandIndependent Non Exe. Director2026
Sunita MaheshwariIndependent Non Exe. Director2026
Somasundaram PalamadairamaswamyIndependent Non Exe. Director2026
Anup WadhawanIndependent Non Exe. Director2026
Ronojit BiswasWhole Time Director & CFO2026
A A NadkarniVP / Company Secretary / Compliance Officer2026
Segments — Product
SegmentRevenueShare
Pharmaceuticals₹0 Cr—
Segments — Geography
RegionRevenueShare
India₹3,783 Cr99.8%
Foreign countries₹7 Cr0.2%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹10180169169
Corporate Actions
TypeDateValueRemark
dividend2026-05-29₹57.0 (570.0%)Final
dividend2026-05-29₹57 (570%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2026678005301,211
2026400004
2026645005301,178
Company Information
Incorporated1924
ChairmanRenu S. Karnad
AuditorDeloitte Haskins & Sells LLP
Investor Email[email protected]; [email protected]
🌐 www.gsk-india.com ↗

📍 GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Giriraj Civil Devp Ltd.Grover Jewells LimitedGK Energy LimitedGujarat Kidney N Sup Sp LimitedGKW LimitedGland Pharma LimitedGlenmark PharmaceuticalsGujarat Lease Financing LimitedGlobal Education LimitedGlobale Tessile LimitedGlobal Pet Industries Ltd.Global Vec Helicorp Ltd.All “G” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search